» Articles » PMID: 18492738

Relative Corticosteroid Insensitivity of Alveolar Macrophages in Severe Asthma Compared with Non-severe Asthma

Overview
Journal Thorax
Date 2008 May 22
PMID 18492738
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Background: About 5-10% of patients with asthma suffer from poorly controlled disease despite corticosteroid (CS) treatment, which may indicate the presence of CS insensitivity. A study was undertaken to determine whether relative CS insensitivity is present in alveolar macrophages from patients with severe asthma and its association with p38 mitogen-activated protein kinase (MAPK) activation and MAPK phosphatase-1 (MKP-1).

Methods: Fibreoptic bronchoscopy and bronchoalveolar lavage (BAL) were performed in 20 patients with severe asthma and 19 with non-severe asthma and, for comparison, in 14 normal volunteers. Alveolar macrophages were exposed to lipopolysaccharide (LPS, 10 mug/ml) and dexamethasone (10(-8) and 10(-6) M). Supernatants were assayed for cytokines using an ELISA-based method. p38 MAPK activity and MKP-1 messenger RNA expression were assayed in cell extracts.

Results: The inhibition of LPS-induced interleukin (IL)1beta, IL6, IL8, monocyte chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1alpha release by dexamethasone (10(-6) M) was significantly less in macrophages from patients with severe asthma than in macrophages from patients with non-severe asthma. There was increased p38 MAPK activation in macrophages from patients with severe asthma. MKP-1 expression induced by dexamethasone and LPS, expressed as a ratio of LPS-induced expression, was reduced in severe asthma.

Conclusion: Alveolar macrophages from patients with severe asthma demonstrate CS insensitivity associated with increased p38 MAPK activation that may result from impaired inducibility of MKP-1.

Citing Articles

MAP3K8 is a potential therapeutic target in airway epithelial inflammation.

Chiu C, Willis-Owen S, Wong K, Farrow S, Cookson W, Moffatt M J Inflamm (Lond). 2024; 21(1):27.

PMID: 39030600 PMC: 11264520. DOI: 10.1186/s12950-024-00400-2.


Bioinformatic analysis and experimental validation of the potential gene in the airway inflammation of steroid-resistant asthma.

Wei C, Wang Y, Hu C Sci Rep. 2023; 13(1):8098.

PMID: 37208441 PMC: 10199006. DOI: 10.1038/s41598-023-35214-4.


Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma.

Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox T Cells. 2023; 12(4).

PMID: 36831258 PMC: 9954069. DOI: 10.3390/cells12040591.


Stress signaler p38 mitogen-activated kinase activation: a cause for concern?.

Radnaa E, Richardson L, Goldman B, Burks J, Baljinnyam T, Vora N Clin Sci (Lond). 2022; 136(22):1591-1614.

PMID: 36250628 PMC: 9664350. DOI: 10.1042/CS20220491.


NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods.

Lee J, Son S, Kim N, Im D Biomol Ther (Seoul). 2022; 31(2):183-192.

PMID: 36171179 PMC: 9970832. DOI: 10.4062/biomolther.2022.078.